UK dominated the European autoimmune disease diagnostics market in 2018 and the industry is projected to achieve similar growth in the forecast period owing to high research and development activities coupled with increasing economic burden of the autoimmune disorders in the country.

With no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights